Sagimet Biosciences (SGMT) Cash & Equivalents (2022 - 2026)

Sagimet Biosciences' Cash & Equivalents history runs 5 years deep, the most recent figure standing at $36.6 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 43.41% year-over-year to $36.6 million; the TTM figure through Mar 2026 stood at $36.6 million (down 43.41% YoY), while the FY2025 annual figure was $35.0 million, down 53.82% from the prior year.
• Cash & Equivalents was $36.6 million for Q1 2026 at Sagimet Biosciences, up from $35.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $176.8 million in Q1 2024 to a low of $158000.0 in Q4 2022.
• Historically, Cash & Equivalents has averaged $64.0 million across 5 years, with a median of $64.7 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents surged 47456.33% in 2023, then sank 63.39% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $158000.0 in 2022, then soared by 47456.33% to $75.1 million in 2023, then grew by 0.93% to $75.8 million in 2024, then plunged by 53.82% to $35.0 million in 2025, then advanced by 4.58% to $36.6 million in 2026.
• The last three Cash & Equivalents figures came in at $36.6 million (Q1 2026), $35.0 million (Q4 2025), and $32.5 million (Q3 2025), per Business Quant data.